MX2007003431A - Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r,*8r*,10r*,11r*)]-10-hidroxi-2-metil- 5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis (fenilmetil)-2,4,7,12-tetraazatridecan-13-oico y un pro - Google Patents

Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r,*8r*,10r*,11r*)]-10-hidroxi-2-metil- 5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis (fenilmetil)-2,4,7,12-tetraazatridecan-13-oico y un pro

Info

Publication number
MX2007003431A
MX2007003431A MX2007003431A MX2007003431A MX2007003431A MX 2007003431 A MX2007003431 A MX 2007003431A MX 2007003431 A MX2007003431 A MX 2007003431A MX 2007003431 A MX2007003431 A MX 2007003431A MX 2007003431 A MX2007003431 A MX 2007003431A
Authority
MX
Mexico
Prior art keywords
methylethyl
thiazolyl
methyl
tetraazatridecan
dioxo
Prior art date
Application number
MX2007003431A
Other languages
English (en)
Inventor
Elvira Beatriz Sini
Fernando Javier Rodriguez
Cecilia Paganitts
Original Assignee
Coll Farma S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coll Farma S L filed Critical Coll Farma S L
Publication of MX2007003431A publication Critical patent/MX2007003431A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5S-(5R*,8R*,10R*,11R*)]-10-hidroxi-2-metil- 5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis (fenilmetil)-2,4,7,12-tetraazatridecan-13-oico y un compuesto que permite la penetracion del fluido gastrointestinal en dicha composicion, el cual se selecciona entre el grupo que comprende los silicatos y el oxido de silice, y un procedimiento para la elaboracion de esta composicion, que comprende una etapa de amasado en la cual se controla estrictamente la velocidad y el tiempo de agregado del solvente.
MX2007003431A 2004-09-28 2005-09-28 Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r,*8r*,10r*,11r*)]-10-hidroxi-2-metil- 5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis (fenilmetil)-2,4,7,12-tetraazatridecan-13-oico y un pro MX2007003431A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ARP040103504A AR045841A1 (es) 2004-09-28 2004-09-28 Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
PCT/ES2005/000524 WO2006037827A1 (es) 2004-09-28 2005-09-28 Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*,8r*,10r*,11r*)]-10 hidroxi-2-metil-5-(1-metiletil)-1-[2-(1-metiletil)-4­ tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12­ tetraazatridecan-13-oico y un procedimiento para prepararla

Publications (1)

Publication Number Publication Date
MX2007003431A true MX2007003431A (es) 2007-08-06

Family

ID=36142313

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007003431A MX2007003431A (es) 2004-09-28 2005-09-28 Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r,*8r*,10r*,11r*)]-10-hidroxi-2-metil- 5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis (fenilmetil)-2,4,7,12-tetraazatridecan-13-oico y un pro

Country Status (7)

Country Link
EP (1) EP1800681B1 (es)
AR (1) AR045841A1 (es)
BR (1) BRPI0515293A (es)
ES (1) ES2390136T3 (es)
MX (1) MX2007003431A (es)
PT (1) PT1800681E (es)
WO (1) WO2006037827A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2601820T3 (es) 2007-02-23 2017-02-16 Gilead Sciences, Inc. Moduladores de propiedades terapéutica de las farmacocinéticas
ES2449074T3 (es) * 2007-06-22 2014-03-18 Bristol-Myers Squibb Holdings Ireland Composiciones en forma de comprimidos que contienen atazanavir
AU2008268537B2 (en) * 2007-06-22 2012-11-01 Bristol-Myers Squibb Holdings Ireland Tableted compositions containing atazanavir
SI2296633T1 (sl) 2008-05-02 2015-11-30 Gilead Sciences, Inc. Uporaba trdnih nosilnih delcev za izboljšanje predelovalnih sposobnosti farmacevtskega sredstva
US20120121722A1 (en) * 2008-12-18 2012-05-17 Anup Avijit Choudhury Atazanavir formulations
WO2013057469A1 (en) * 2011-10-20 2013-04-25 Cipla Limited Pharmaceutical antiretroviral compositions
MX2016002560A (es) * 2013-08-29 2016-10-26 Teva Pharma Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264020B (it) * 1993-01-28 1996-09-09 Recordati Chem Pharm Procedimento per la preparazione di microgranuli idonei alla sospensione in liquidi
GB9622681D0 (en) * 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions
CN1154491C (zh) * 1998-11-04 2004-06-23 法玛西雅厄普约翰美国公司 用于改善替普拉那维的药物动力学的方法
US7205413B2 (en) * 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
JP2006056781A (ja) * 2002-11-15 2006-03-02 Bioserentack Co Ltd 界面活性剤を含む固形化製剤
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation

Also Published As

Publication number Publication date
EP1800681B1 (en) 2012-06-27
EP1800681A1 (en) 2007-06-27
AR045841A1 (es) 2005-11-16
WO2006037827A1 (es) 2006-04-13
ES2390136T3 (es) 2012-11-07
BRPI0515293A (pt) 2008-07-15
PT1800681E (pt) 2012-10-03

Similar Documents

Publication Publication Date Title
MX2007003431A (es) Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r,*8r*,10r*,11r*)]-10-hidroxi-2-metil- 5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis (fenilmetil)-2,4,7,12-tetraazatridecan-13-oico y un pro
WO2008021927A3 (en) Hepatitis c virus inhibitors
WO2008005877A3 (en) Inhibitors of c-kit and uses thereof
EA018193B3 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
WO2006033700A3 (en) Her2 antibody composition
WO2008106130A3 (en) Tertiary amine substituted peptides useful as inhibitors of hcv replication
WO2006023496A3 (en) Vaginal cream compositions, kits thereof and methods of using thereof
WO2004112742A3 (fr) Extrait de maca et composition cosmetique comprenant un tel extrait
WO2007008657A3 (en) Hepatitis c virus inhibitors
DE60115383D1 (de) Hochreine lipopeptide, lipopeptid mizellen, deren herstellung und arzneimittel
WO2009130204A3 (en) Improved formulations for poorly permeable active pharmaceutical ingredients
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
WO2006060681A3 (en) Pharmaceutical composition containing an anti-nucleating agent
AR049658A2 (es) Ritonavir amorfo, su uso en la fabricacion de un medicamento, composicion farmaceutica, proceso para su preparacion y proceso para la preparacion de la forma polimorfa cristalina i de ritonavir.
WO2009107983A3 (ko) 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
WO2008070350A3 (en) Methods and compositions related to wrapping of dehydrons
WO2008039472A3 (en) Stabilizing compositions for antibiotics and methods of use
WO2008115385A3 (en) Piperazine-substituted pyridazinone derivatives useful as glucan synthase inhibitors
EA200701680A1 (ru) Лекарственная форма для перорального введения, содержащая розиглитазон
EE200200655A (et) 5-kloro-3-(4-metaansulfonüülfenüül)-6'-metüül[2,3']bipüridinüüli polümorfne vorm, selle valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
WO2007017585A3 (fr) Nouveaux composes analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2005079759A3 (en) Pharmaceutical composition for oral application and method for preparing thereof
WO2008117875A1 (ja) 口腔咽喉用組成物
WO2002026737A8 (en) Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
UA122762C2 (uk) Пероральна композиція 9-[(2,2-диметилпропіламіно)-метил]-міноцикліну або його солі, тверда пресована дозована форма, композиція для ін'єкцій, застосування та спосіб приготування фармацевтичної композиції

Legal Events

Date Code Title Description
FG Grant or registration